Navigation Links
iCardiac's Highly Automated QT(sm) Technology Cross-Validated Against Results from Five Leading ECG Core Laboratories
Date:5/11/2009

Results Based on FDA's ECG Data Warehouse and Shared at 2009 Drug Information Association Conference

Rochester, NY (PRWEB) May 11, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety biomarker development, today announced that the company's Highly Automated QT technology has now been validated against manual or semi-automated measurements made by five leading ECG core laboratories. The data for the analysis comprised a total of six independent Thorough QT (TQT) studies stored in FDA's ECG warehouse. The results of the validation study found the measurements made by Highly Automated QT to be statistically consistent with the measurements made independently and in a blinded fashion by the core laboratories.

"This is an important step for cardiac safety testing," said Sasha Latypova, Executive Vice President at iCardiac. "Given these results, pharmaceutical companies can be confident in using the Highly Automated QT technology in their cardiac safety studies to increase the robustness of their study results, as well as to drive cost reductions in their development process."

The Highly Automated QT technology, which iCardiac has licensed from the University of Rochester, is unique in the industry because it combines advanced ECG signal processing with a quality assurance process involving cardiologists. With this approach, only a small portion of the entire Thorough QT (TQT) dataset requires manual over-reading, thereby generating significant cost and time savings to sponsors while at the same time providing assurance to the regulators regarding data quality.

In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2

Related medicine news :

1. iCardiac's Highly Automated QT(sm) Technology Now Validated in Over 10 Clinical QT Studies
2. VARI researcher chosen for highly competitive Scholar-in-Training Award
3. Dr.Khanna Featured in Highly Respected Trade Journal
4. Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients
5. A New, Highly Effective, Non-Narcotic Pain Medication Now Available for Chronic Pain Patients
6. Perlabella Introduces a Highly Concentrated and Affordable Anti-Aging Skin Care Line
7. Yankees Will Become First MLB Team to Integrate Highly Advanced Antimicrobial System
8. Specialists are Highly Satisfied with the Safety and Efficacy of Atripla and Isentress in the Treatment of HIV Patients
9. Pennsylvania Health Department Offers Tips to Prevent Spread of Highly Contagious Norovirus
10. Choosing a Highly-Trained Bariatric Surgeon Crucial as Surgical Weight Loss Procedures Rise and Less-Qualified Doctors Flood the Market
11. Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... It,s not uncommon these days to find a colored ribbon ... signify breast cancer. But what color ribbon does one think ... the designated color, for many suffering from the disease, black ... State University study consisting of lung cancer patients, primarily smokers ... shedding more light on the stigma often felt by these ...
(Date:4/17/2014)... 40 years away from a food shortage that will ... a top scientist at the U.S. Agency for International ... production will be limited on a global scale by ... Fred Davies, senior science advisor for the agency,s bureau ... destabilizing by 2050 as energy issues are today.", Davies, ...
(Date:4/17/2014)... TORONTO, April 17, 2014 Giving patients adrenaline after they ... not increase their prospects of surviving long-term, according to ... vast number of patients who have a cardiac arrest ... treating cardiac arrest for decades," said Dr. Steve Lin, ... Michael,s. "Yet, despite advances in medical treatment, long-term survival ...
(Date:4/17/2014)... called for more research to be carried out ... sub-Saharan Africa. In a paper in The ... working with colleagues in the department of Parasitology ... Cleveland Ohio, University of Cambridge and the Royal ... joint burden of HIV/AIDS and schistosomiasis of children, ...
Breaking Medicine News(10 mins):Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:More research called for into HIV and schistosomiasis coinfection in African children 2
... , AVENTURA, Fla., Dec. 21 Cinergy ... benefit programs for the consumer market, expressed its concern for the ... this morning. , "While the Senate and House healthcare bills are ... step towards expanding access to affordable health coverage for all Americans," ...
... on edibles that will signal fullness just by chewing ... possible to create foods with hunger-suppressing aromas that would offer ... scientists say. , Researchers have long attempted to develop foods ... until recently, have focused on the effects of food in ...
... powerful results in mice and people, researchers say , ... a protein that may be involved in the development ... to new drugs to fight this growing worldwide scourge. ... inhibiting this pathway worked to block pain associated with ...
... ... schedules have been finalized for the ,second annual Dr. Alec Kessler Memorial High School ... Center., , ... (Vocus) December 21, 2009 -- The teams and the tournament schedules have been finalized for ...
... , BOCA RATON, Fla., Dec. 21 Flipping ... system for children and adults, has teamed up with Fisher ... to the retail value of $10,000 - to the children ... In an effort to make the holidays a bit ...
... , , AARP PENNSYLVANIA KEY VOTE NEWS ALERT , ATTENTION ... on key issues throughout the 111th Congress, and informing its nearly ... these key votes. , HARRISBURG, Pa., Dec. 21 The U.S. ... that will begin to bring needed relief to millions of Americans ...
Cached Medicine News:Health News:Cinergy Health Commentary on Senate Healthcare Vote 2Health News:Diabetes Insight Could Lead to Better Treatments 2Health News:Teams And Tournament Schedule Finalized For The Dr. Alec Kessler Memorial High School Basketball Invitational December 28-30, 2009 2Health News:Teams And Tournament Schedule Finalized For The Dr. Alec Kessler Memorial High School Basketball Invitational December 28-30, 2009 3Health News:Flipping for Phonics(TM) Helps Spread Cheer To Military Families In Fisher Houses(R) This Holiday Season 2Health News:Flipping for Phonics(TM) Helps Spread Cheer To Military Families In Fisher Houses(R) This Holiday Season 3Health News:AARP Applauds Senate for Moving Health Care Reform Forward 2Health News:AARP Applauds Senate for Moving Health Care Reform Forward 3
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Presented Along With Updated Phase 1 Colorectal Cancer ... Data at ... CHICAGO, June 1 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... results,from its ongoing randomized Phase 2 clinical trial in patients ...
... Greater Than 50% Response Rate and 100% Disease Control Rate Observed ... Patients with Medullary Thyroid Cancer, ... encouraging new data from an ongoing phase 1 clinical trial of,XL184, ... with advanced malignancies. The maximum tolerated dose (MTD) for,XL184 has been ...
Cached Medicine Technology:Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 2Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 3Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 4Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6
The UniCel DxI 800 with its exceptional throughput, proven chemiluminescent technology, assay protocols like Access, Access 2, Synchron LXi 725 and load "on-the-fly" capability simplifies and automat...
... The Access immunoassay system ... access benchtop analyzer that ... assays, with panels that ... thyroid, infectious disease, blood ...
...
...
Medicine Products: